The company is advancing a set of high-value programs across its core areas of focus including hematology, immunology and oncology, liver, and lung. In November 2025, Prime appointed Matthew Hawryluk as Chief Business Officer to lead corporate and business development, corporate strategy, and alliance management to expand Prime Editing through strategic partnerships.
Cyborg Score Rationale
Prime Medicine is at an early clinical stage with promising Prime Editing technology, but faces typical biotech risks including cash burn and clinical execution risk. The company reported R&D spending of $44.0M and net loss of $50.6M for Q3 2025, though cash and equivalents totaled $227.0M expected to sustain operations into 2027.
Top Insights
Q3 2025 results showed Wilson's Disease program (PM577) IND/CTA filing expected in H1 2026 with clinical data in 2027, and PM647 nominated for Alpha-1 Antitrypsin Deficiency with mid-2026 IND/CTA filing planned.
The company demonstrated initial human safety and efficacy for Prime Editing in 2025 clinical data.
Average 12-month price target is $6.46 with 7 analysts recommending buy and 0 recommending sell.
Prime has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases and blood cancers.
Named Competitors
CRISPR Gene Editing — CRISPR-based in vivo gene editing therapies